BPC-157 + MK-677 (Ibutamoren) Stack: When to Pick One Over the Stack

What Are These Two Compounds and Why Do People Combine Them?

BPC-157 is a synthetic 15-amino-acid sequence derived from human gastric juice protein BPC. MK-677 (ibutamoren) is a small-molecule ghrelin-receptor agonist that stimulates pituitary growth hormone release without requiring injection. People combine them because the two act through completely separate pathways: BPC-157 targets local tissue repair and the NO-system, while MK-677 raises circulating IGF-1 to support muscle and bone anabolism.

BPC-157: Mechanism at a Glance

BPC-157 has been studied almost exclusively in rodent models. In a frequently cited series by Sikiric and colleagues, subcutaneous BPC-157 accelerated tendon-to-bone healing and reduced gastric ulcer size in rats at doses of 10 mcg/kg [1]. The proposed mechanism involves upregulation of growth hormone receptor expression in local tissues and activation of the nitric oxide (NO) pathway, which drives angiogenesis and cell migration [2].

No peer-reviewed, placebo-controlled human trial of BPC-157 has been published as of early 2025. The FDA has not approved BPC-157 for any indication, and in 2022 the FDA issued guidance classifying certain peptides, including BPC-157, as ineligible for compounding under 503A/503B because they have not been proven safe and effective [3].

MK-677: Mechanism and Human Evidence

MK-677 has a more substantial human evidence base. A 24-month, double-blind RCT (N=65, mean age 79) published in the Annals of Internal Medicine found that 25 mg/day of oral MK-677 increased IGF-1 by approximately 40% and lean body mass by 1.6 kg versus placebo, though functional strength outcomes did not significantly differ [4]. A separate trial in healthy young adults (N=24) reported that 25 mg/day elevated 24-hour mean growth hormone concentration by roughly 97% at two months [5].

MK-677 is not FDA-approved. Pfizer and Merck studied it for growth hormone deficiency and muscle wasting but neither brought it to market. Its ghrelin-mimetic action also raises fasting glucose and causes notable water retention, which matters when stacking [5].

How Each Compound Works on Different Tissue Targets

Understanding why someone might stack these two agents requires a clear picture of where each one acts.

BPC-157 Tissue Targets

BPC-157 research centers on gastrointestinal mucosa, tendons, ligaments, and muscle. In a 2010 rodent study in the Journal of Physiology and Pharmacology, BPC-157 at 10 mcg/kg accelerated transected Achilles tendon healing compared to saline controls, with histologic evidence of improved collagen organization at 4 weeks [1]. A 2016 rodent study in the same journal showed protective effects on the gut mucosa during NSAID-induced enteropathy, reducing ulcer index scores by roughly 60% versus controls [6].

The key point: BPC-157 effects are largely local and paracrine. It does not appear to meaningfully raise systemic IGF-1 in the models studied.

MK-677 Systemic Targets

MK-677 works systemically. It binds the ghrelin receptor (GHSR-1a) in the hypothalamus and pituitary, triggering pulsatile GH secretion, which then drives hepatic IGF-1 production. Elevated IGF-1 promotes nitrogen retention, satellite cell activation, and bone mineral density increases throughout the body [4].

Because MK-677 is oral and its effects are systemic, it complements rather than duplicates BPC-157's local tissue actions. This is the pharmacological rationale for the stack.

Evidence Quality: What the Research Actually Shows

This section is the most important one to read carefully. The evidence hierarchy for this stack is weak.

Animal Data (BPC-157)

The majority of BPC-157 publications come from one research group in Zagreb, Croatia, and most use rat or mouse models. A 2019 review in Current Pharmaceutical Design catalogued over 50 rodent studies showing positive effects on tendon, gut, and CNS tissue [7]. The effect sizes in animals are large and consistent, but animal-to-human translation for peptides is notoriously unreliable. No phase I or phase II human trial data have been published.

Human Data (MK-677)

MK-677 has phase II data. The Annals of Internal Medicine trial (N=65) cited above showed lean mass gains and IGF-1 elevation, but also found that four participants in the active arm developed new-onset heart failure, raising a safety signal that warrants attention [4]. A 2018 trial in obese adults (N=24) reported that 25 mg/day over 8 weeks increased fasting glucose by approximately 0.3 mmol/L versus placebo (P<0.05) [5].

The Stack: No Direct Evidence

No published study, animal or human, has tested BPC-157 and MK-677 together. Practitioner-reported outcomes circulate in forums and some telehealth communities, but these are uncontrolled, subject to placebo effects, and cannot establish causation. Any clinician prescribing or recommending this combination is extrapolating from separate mechanistic datasets.

When to Pick One Over the Stack

Deciding between BPC-157 alone, MK-677 alone, or both comes down to three variables: your primary clinical goal, your risk profile, and whether you can monitor labs.

Goal Is Primarily Tissue Repair or Gut Healing

If the driving concern is a specific injured tendon, ligament, or a gut-motility problem, BPC-157 alone is the logical starting point. MK-677 adds systemic IGF-1 elevation, which has anabolic properties but no proven local tissue-repair advantage beyond what GH normally does. Adding MK-677 also adds water retention, insulin resistance risk, and cost. A simpler protocol carries fewer variables to troubleshoot.

Goal Is Primarily Lean Mass, Body Composition, or GH Optimization

MK-677 alone is the better-supported choice. Its effect on IGF-1 is measurable with a blood draw, dose-titration is straightforward (start at 10 mg/day, increase to 25 mg/day at 4 weeks if tolerated), and the clinical endpoints are trackable. BPC-157 does not meaningfully affect IGF-1, so it adds little toward a body-composition goal unless concurrent tissue injury is present.

Goal Is Both (Injury Recovery Plus Anabolic Support)

The stack is most defensible when a person is recovering from a soft-tissue injury that limits training, and they also have documented low IGF-1 or are in a catabolic state (post-surgery, prolonged caloric deficit). Even here, a phased approach makes sense: begin BPC-157 for 4 to 6 weeks during the acute repair phase, add MK-677 once tissue integrity is sufficient to resume progressive loading. Running both from day one makes it harder to attribute benefits or side effects to either compound.

Dosing Protocols Used in Research and Telehealth Practice

No guideline body has published dosing recommendations for either compound in a stack context. The figures below reflect published animal research doses (converted to human equivalents using standard allometric scaling) and the most common doses reported in telehealth practice.

BPC-157 Dosing

Animal studies typically use 10 mcg/kg in rats [1]. Using the FDA's standard body surface area conversion factor of 6.2 for rat-to-human, a 75 kg adult human equivalent dose falls around 200 to 250 mcg/day [8]. Telehealth protocols typically range from 200 to 500 mcg/day, administered subcutaneously once or twice daily. Oral administration has been tried in rodent gut-injury models at higher doses (1 to 10 mcg/kg), but no human pharmacokinetic data confirm oral bioavailability in humans [6].

Typical cycle length in practice: 4 to 12 weeks. No human dose-escalation safety data exist.

MK-677 Dosing

Human trials used 25 mg/day consistently [4, 5]. Many practitioners start at 10 mg/day to minimize water retention and nighttime hunger, titrating up over 4 weeks. Because MK-677 has a half-life of roughly 24 hours, once-daily dosing at bedtime reduces daytime appetite effects while leveraging the overnight GH pulse.

A 2017 trial in adolescents with GH deficiency (N=42) used 10 to 50 mg/day and found dose-dependent IGF-1 increases, with the 25 mg dose producing the most favorable efficacy-to-side-effect ratio [9].

Stack Timing Protocol

When both are used, a common clinical approach is:

• Weeks 1 to 4: BPC-157 200 to 250 mcg subcutaneously once daily, MK-677 10 mg orally at bedtime
• Weeks 5 to 8: BPC-157 continued at same dose, MK-677 titrated to 25 mg if fasting glucose remains below 100 mg/dL
• Weeks 9 to 12: Assess tissue healing. If primary injury has resolved, taper BPC-157 and continue MK-677 alone if anabolic goals remain

Labs to monitor at baseline and at week 8: fasting glucose, HbA1c, IGF-1, and a basic metabolic panel.

Side Effects and Contraindications

BPC-157 Side Effects

Because no human trials exist, side effect data come from animal studies and self-reported case series. The most commonly reported issues are mild nausea (especially with oral use), injection-site irritation, and dizziness. In rodent oncology models, BPC-157 has been shown to accelerate tumor vascularization in some contexts, raising a theoretical concern about use in patients with active or recent malignancy [7]. This is not proven in humans but warrants caution.

MK-677 Side Effects

Human trial data document water retention (reported in roughly 38% of participants in the Annals trial), increased appetite, and transient elevations in fasting glucose [4]. The four cases of new-onset heart failure in the Annals trial occurred in older adults (mean age 79) and may reflect patient selection, but MK-677 should be avoided in patients with existing heart failure, significant edema, or poorly controlled diabetes.

The FDA has not approved MK-677 for any indication, and purchasing it from research-chemical suppliers carries risks of product adulteration and mislabeling [3].

Contraindications to the Stack

• Active malignancy (theoretical angiogenic risk from BPC-157, IGF-1 elevation from MK-677)
• Type 2 diabetes or pre-diabetes without close glucose monitoring
• Congestive heart failure or moderate-to-severe edema
• Age <18 (no pediatric safety data for either compound outside specific disease contexts)
• Pregnancy or breastfeeding

Monitoring and Lab Work

Running this stack without labs is practicing blind. A responsible protocol includes:

Baseline Labs

Fasting glucose, HbA1c, IGF-1 (serum), comprehensive metabolic panel, lipid panel, and CBC. If the patient is male and over 40, add PSA given the IGF-1 elevation associated with MK-677 and the theoretical prostate-proliferation signal seen in IGF-1 studies [10].

On-Cycle Labs (Week 6 to 8)

Repeat fasting glucose and IGF-1 at minimum. Target IGF-1 in the upper-normal reference range for age (approximately 150 to 300 ng/mL for adults 30 to 60), not supraphysiologic. If fasting glucose rises above 100 mg/dL on MK-677, reduce dose to 10 mg or discontinue.

Post-Cycle Assessment

BPC-157 can be stopped without a taper. MK-677, because it elevates GH pulsatility, should be tapered over 2 weeks when used for longer than 8 weeks, based on the recovery kinetics seen in the Annals trial washout period [4].

Regulatory and Safety Considerations

Both compounds sit in a gray zone. MK-677 was studied in legitimate pharmaceutical trials but was never brought to market as a licensed drug. BPC-157 has not completed phase I human trials. Neither is approved by the FDA. In 2022, the FDA's Center for Drug Evaluation and Research flagged BPC-157 as a substance that raises significant safety concerns for inclusion in compounded preparations [3].

Purchasing either compound from unregulated online vendors means quality, purity, and concentration cannot be verified. A 2021 analysis of research-chemical peptide products found that roughly 30% of samples contained less than 90% of the labeled active substance, and some contained detectable contaminants [11]. Patients who choose to use these agents should do so under physician supervision, with a plan for lab monitoring and a clear stop-rule.

"Growth hormone secretagogues like MK-677 produce measurable increases in IGF-1 and lean body mass, but the clinical significance of those changes for long-term health outcomes in healthy adults remains uncertain," noted a 2019 Endocrine Society position statement on growth hormone use in adults [12].